Erratum: A systematic comparison of the anti-tumoural activity and toxicity of the three adv-tks (PLoS ONE 9:4 (e94050) (DOI:10.1371/journal.pone.0094050);A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Gao, Qinglei ^a   Chen, Caihong ^b   Ji, Teng ^a   Wu, Peng ^a   Han, Zhiqiang ^a   Fang, Haiyan ^a   Li, Fei ^a   Liu, Yi ^a   Hu, Wencheng ^a   Gong, Danni ^a   Zhang, Zeyu ^c   Wang, Shixuan ^a   Zhou, Jianfeng ^a   Ding, Ma ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC ADENOVIRUS; THYMIDINE KINASE; ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; STOMACH CARCINOMA; SYRIAN HAMSTER; SYSTEMIC THERAPY; TRANSGENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; COMPARATIVE STUDY; ENZYMOLOGY; FLOW CYTOMETRY; GENE VECTOR; GENETICS; HAMSTER; HEK293 CELL LINE; HEPG2 CELL LINE; MESOCRICETUS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PROCEDURES; STOMACH NEOPLASMS; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CRICETINAE; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HEK293 CELLS; HEP G2 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; STOMACH NEOPLASMS; THYMIDINE KINASE; TRANSGENES;

EID: 84899538705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153540     Document Type: Erratum

References (41)

1. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, et al. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62: 6070-6079. (Pubitemid 35244455)
2. Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG (2002) Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther 6: 287-297. (Pubitemid 36336138)
3. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, et al. (2002) Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 13: 15-63. (Pubitemid 34075172)
4. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, et al. (2002) Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 9: 254-259. (Pubitemid 34205499)
5. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, et al. (2001) Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 4: 182-191. (Pubitemid 32851281)
6. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, et al. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8: 1618-1626. (Pubitemid 33085583)
7. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12: 219-226. (Pubitemid 32163894)
8. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, et al. (1999) Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 73: 6729-6742. (Pubitemid 29327856)
9. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, et al. (1997) Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5- fluorocytosine. Hum Gene Ther 8: 985-1001. (Pubitemid 27270161)
10. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, et al. (2003) Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 9: 693-702. (Pubitemid 36182602)
11. Mesnil M, Yamasaki H (2000) Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 60: 3989-3999. (Pubitemid 30636571)
12. Yazawa K, Fisher WE, Brunicardi FC (2002) Current progress in suicide gene therapy for cancer. World J Surg 26: 783-789. (Pubitemid 36920318)
13. Li N, Zhou J, Weng D, Zhang C, Li L, et al. (2007) Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 13: 5847-5854. (Pubitemid 47583910)
14. Kirn D (2000) Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19: 6660-6669.
15. Zhou J, Gao Q, Chen G, Huang X, Lu Y, et al. (2005) Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 11: 8431-8440. (Pubitemid 41746958)
16. Han Z, Hong Z, Chen C, Gao Q, Luo D, et al. (2009) A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis 30: 2014-2022.
17. Gao Q, Zhou J, Huang X, Chen G, Ye F, et al. (2006) Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther 13: 928-937.
18. Huang X, Zhuang L, Cao Y, Gao Q, Han Z, et al. (2008) Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration. Mol Cancer Ther 7: 1624-1632.
19. Chen G, Zhou J, Gao Q, Huang X, Li K, et al. (2006) Oncolytic adenovirus-mediated transfer of the anti-sense Chk2 selectively inhibits tumor growth in vitro and in vivo. Cancer Gene Therapy, 13: 930-939. (Pubitemid 44373793)
20. Li N, Zhou J, Weng D, Zhang C, Li L, et al. (2007) Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 13(19): 5847-5854. (Pubitemid 47583910)
21. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, et al. (1999) Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 11: 380-386. (Pubitemid 29377903)
22. Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, et al. (2001) Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 276: 3270-3278.
23. Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, et al. (2001) Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7K/gp19K region. Gene Ther 8: 1123-1131. (Pubitemid 32776385)
24. Tollefson AE, Scaria A, Saha SK, Wold WS (1992) The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol 66: 3633-3642.
25. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS (1996) The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220: 152-162. (Pubitemid 26201673)
26. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, et al. (1996) The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296-2306. (Pubitemid 26087592)
27. Tollefson AE, Scaria A, Ying B, Wold WS (2003) Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells. J Virol 77: 7764-7778. (Pubitemid 36792773)
28. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, et al. (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464-7472. (Pubitemid 32995035)
29. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806. (Pubitemid 30159332)
30. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, et al. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437-445. (Pubitemid 40394296)
31. Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, et al. (2007) Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 196: 389 e381-389; discussion 389 e389-310.
32. Su C, Cao H, Tan S, Huang Y, Jia X, et al. (2008) Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci 106: 242-250.
33. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506. (Pubitemid 37413494)
34. Wang Y, Hallden G, Hill R, Anand A, Liu TC, et al. (2003) E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335. (Pubitemid 37356618)
35. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, et al. (2009) An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther, 16(8): 644-654.
36. Ketner G, Boyer J (2007) Isolation, growth, and purification of defective adenovirus deletion mutants. Methods Mol Med 130: 19-28.
37. Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY (1997) Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 90: 2738-2746. (Pubitemid 27413484)
38. Kurbacher CM, Korn C, Dexel S, Schween U, Kurbacher JA, et al. (2011) Isolation and culture of ovarian cancer cells and cell lines. Methods Mol Biol 731: 161-180.
39. Wu P, Meng L, Wang H, Zhou J, Xu G, et al. (2005) Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor. Biochem Biophys Res Commun 335: 36-44. (Pubitemid 41350760)
40. Zheng FQ, Xu Y, Yang RJ, Wu B, Tan XH, et al. (2009) Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin 30: 617-627.
41. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, et al. (2008) Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 16: 1665-1673.